| 000 | 01857 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514205624.0 | ||
| 264 | 0 | _c20041221 | |
| 008 | 200412s 0 0 eng d | ||
| 022 | _a0066-4804 | ||
| 024 | 7 |
_a10.1128/AAC.48.11.4473-4475.2004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGurumurthy, Prema | |
| 245 | 0 | 0 |
_aDecreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cNov 2004 |
||
| 300 |
_a4473-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAcetylation |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibiotics, Antitubercular _xpharmacokinetics |
| 650 | 0 | 4 |
_aAntitubercular Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aEthambutol _xpharmacokinetics |
| 650 | 0 | 4 |
_aFeces _xmicrobiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntestinal Absorption |
| 650 | 0 | 4 |
_aIsoniazid _xpharmacokinetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aPyrazinamide _xpharmacokinetics |
| 650 | 0 | 4 |
_aRifampin _xpharmacokinetics |
| 650 | 0 | 4 |
_aTuberculosis _xcomplications |
| 700 | 1 | _aRamachandran, Geetha | |
| 700 | 1 | _aHemanth Kumar, A K | |
| 700 | 1 | _aRajasekaran, S | |
| 700 | 1 | _aPadmapriyadarsini, C | |
| 700 | 1 | _aSwaminathan, Soumya | |
| 700 | 1 | _aBhagavathy, S | |
| 700 | 1 | _aVenkatesan, P | |
| 700 | 1 | _aSekar, L | |
| 700 | 1 | _aMahilmaran, A | |
| 700 | 1 | _aRavichandran, N | |
| 700 | 1 | _aParamesh, P | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 48 _gno. 11 _gp. 4473-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.48.11.4473-4475.2004 _zAvailable from publisher's website |
| 999 |
_c15193948 _d15193948 |
||